Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization

Haematologica

Volumn 101, Issue 9, 2016, Pages 1028-1038

  Godefroy, Emmanuelle ^a   Liu, Yunfeng ^a   Shi, Patricia ^a   Beau Mitchell, W ^a   Cohen, Devin ^b   Chou, Stella T ^b   Manwani, Deepa ^c   Yazdanbakhsh, Karina ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD83 ANTIGEN; GAMMA INTERFERON; HEME; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; TOLL LIKE RECEPTOR 4; ALLOANTIBODY; BIOLOGICAL MARKER; CYTOKINE; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ADOLESCENT; ADULT; ALLOIMMUNIZATION; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; PERIPHERAL BLOOD MONONUCLEAR CELL; RECEPTOR DOWN REGULATION; SICKLE CELL ANEMIA; ADVERSE EFFECTS; ANEMIA, SICKLE CELL; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD TRANSFUSION; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MONOCYTE; T LYMPHOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTIGENS, CD; BIOMARKERS; BLOOD TRANSFUSION; CYTOKINES; DENDRITIC CELLS; FEMALE; HEME; HEME OXYGENASE-1; HUMANS; IMMUNOGLOBULINS; ISOANTIBODIES; MALE; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; MONOCYTES; NF-KAPPA B; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4; YOUNG ADULT;

EID: 84986216143     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.147181     Document Type: Article

References (46)

1. Frenette PS, Atweh GF. Sickle cell disease:old discoveries, new concepts, and future promise. J Clin Invest. 2007;117(4):850-858.
2. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: Pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3):528-537.
3. Bao W, Zhong H, Li X, et al. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and beta-thalassemia major. Am J Hematol. 2011;86(12):1001-1006.
4. Godefroy E, Zhong H, Pham P, Friedman D, Yazdanbakhsh K. TIGIT-positive circulating follicular helper T cells display robust Bcell help functions: Potential role in sickle cell alloimmunization. Haematologica. 2015;100(11):1415-1425.
5. Nickel RS, Horan JT, Fasano RM, et al. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. Am J Hematol. 2015;90(12):1135-1141.
6. Vingert B, Tamagne M, Desmarets M, et al. Partial dysfunction of Treg activation in sickle cell disease. Am J Hematol. 2014;89(3):261-266.
7. Vingert B, Tamagne M, Habibi A, et al. Phenotypic differences of CD4(+) T cells in response to red blood cell immunization in transfused sickle cell disease patients. Eur J Immunol. 2015;45(6):1868-1879.
8. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: Exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121(8):1276-1284.
9. Zhong H, Bao W, Friedman D, Yazdanbakhsh K. Hemin controls T cell polarization in sickle cell alloimmunization. J Immunol. 2014;193(1):102-110.
10. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
11. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-252.
12. Hivroz C, Chemin K, Tourret M, Bohineust A. Crosstalk between T lymphocytes and dendritic cells. Crit Rev Immunol. 2012;32(2):139-155.
13. Chauveau C, Remy S, Royer PJ, et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood. 2005;106(5):1694-1702.
14. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377-390.
15. Dutra FF, Alves LS, Rodrigues D, et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci USA. 2014;111(39):E4110-4118.
16. Fortes GB, Alves LS, de Oliveira R, et al. Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production. Blood. 2012;119(10):2368-2375.
17. Vercellotti GM. Look out heme, Mac is back in town. Blood. 2014;124(9):1388-1389.
18. Vinchi F, Costa da Silva M, Ingoglia G, et al. Hemopexin therapy reverts heme-induced pro-inflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood. 2016;127(4):473-486.
19. Trinchieri G. Role of interleukin-12 in human Th1 response. Chem Immunol. 1996;63:14-29.
20. Bogunovic D, Manches O, Godefroy E, et al. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res. 2011;71(16):5467-5476.
21. Skoberne M, Somersan S, Almodovar W, et al. The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic- cell immunostimulatory function. Blood. 2006;108(3):947-955.
22. Remy S, Blancou P, Tesson L, et al. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. J Immunol. 2009;182(4):1877-1884.
23. Chora AA, Fontoura P, Cunha A, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest. 2007;117(2):438-447.
24. Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med. 2000;6(4):422-428.
25. Ryter SW, Choi AM. Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation. Transl Res. 2016;167(1):7-34.
26. Soares MP, Marguti I, Cunha A, Larsen R. Immunoregulatory effects of HO-1: How does it work? Curr Opin Pharmacol. 2009; 9(4):482-489.
27. Wagener FA, Volk HD, Willis D, et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev. 2003;55(3):551-571.
28. Santos-Silva T, Mukhopadhyay A, Seixas JD, Bernardes GJ, Romao CC, Romao MJ. Towards improved therapeutic CORMs:understanding the reactivity of CORM-3 with proteins. Curr Med Chem. 2011;18(22):3361-3366.
29. Jozkowicz A, Dulak J. Effects of protoporphyrins on production of nitric oxide and expression of vascular endothelial growth factor in vascular smooth muscle cells and macrophages. Acta Biochim Pol. 2003;50(1):69-79.
30. Figueiredo RT, Fernandez PL, Mourao-Sa DS, et al. Characterization of heme as acti vator of Toll-like receptor 4. J Biol Chem. 2007;282(28):20221-20229.
31. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123(11):4809-4820.
32. Lin S, Yin Q, Zhong Q, et al. Heme activates TLR4-mediated inflammatory injury via MyD88/TRIF signaling pathway in intracerebral hemorrhage. J Neuroinflammation. 2012;9:46.
33. Mogami H, Kishore AH, Shi H, Keller PW, Akgul Y, Word RA. Fetal fibronectin signaling induces matrix metalloproteases and cyclooxygenase-2 (COX-2) in amnion cells and preterm birth in mice. J Biol Chem. 2013;288(3):1953-1966.
34. Stein MF, Lang S, Winkler TH, et al. Multiple interferon regulatory factor and NF-kappaB sites cooperate in mediating cell-type- and maturation-specific activation of the human CD83 promoter in dendritic cells. Mol Cell Biol. 2013;33(7):1331-1344.
35. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendriticcell defects. Nat Rev Immunol. 2004;4(12):941-952.
36. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006;16(1):53-65.
37. Solito S, Pinton L, Damuzzo V, Mandruzzato S. Highlights on molecular mechanisms of MDSC-mediated immune suppression: Paving the way for new working hypotheses. Immunol Invest. 2012;41(6-7):722-737.
38. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: A case series. Transfusion. 2016;56(1):107-114.
39. Fujimoto Y, Tu L, Miller AS, et al. CD83 expression influences CD4+ T cell development in the thymus. Cell. 2002;108(6):755-767.
40. Garcia-Martinez LF, Appleby MW, Staehling-Hampton K, et al. A novel mutation in CD83 results in the development of a unique population of CD4+ T cells. J Immunol. 2004;173(5):2995-3001.
41. Kruse M, Rosorius O, Kratzer F, et al. Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J Exp Med. 2000;191(9):1581-1590.
42. Al-Huseini LM, Aw Yeang HX, Hamdam JM, et al. Heme oxygenase-1 regulates dendritic cell function through modulation of p38 MAPK-CREB/ATF1 signaling. J Biol Chem. 2014;289(23):16442-16451.
43. Wang XM, Kim HP, Nakahira K, Ryter SW, Choi AM. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. J Immunol. 2009;182(6):3809-3818.
44. Seldon MP, Silva G, Pejanovic N, et al. Heme oxygenase-1 inhibits the expression of adhesion molecules associated with endothelial cell activation via inhibition of NF-kappaB RelA phosphorylation at serine 276. J Immunol. 2007;179(11):7840-7851.
45. Ardeshna KM, Pizzey AR, Devereux S, Khwaja A. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood. 2000;96(3):1039-1046.
46. Prazma CM, Tedder TF. Dendritic cell CD83: A therapeutic target or innocent bystander? Immunol Lett. 2008;115(1):1-8.